Key result
Preexisting coronary artery disease in patients undergoing MitraClip was associated with higher in-hospital acute myocardial infarction (1.6% vs 0.4%, p<0.01) but similar mortality (2.2% vs 2.6%).
Why the study?
It is unclear whether the presence of preexisting coronary arterial disease affects postprocedural outcomes of percutaneous mitral valve repair with MitraClip.
Does preexisting coronary arterial disease affect postprocedural outcomes in patients undergoing percutaneous mitral valve repair?
Cohort (n=2,539)
Yes
Does preexisting coronary arterial disease affect postprocedural outcomes in patients undergoing percutaneous mitral valve repair?
In patients undergoing percutaneous mitral valve repair, preexisting CAD is associated with higher in-hospital AMI but comparable mortality and 30-day readmission, whereas concurrent PCI significantly increases mortality and morbidity.
Warrants periprocedural MI vigilance in CAD patients undergoing MitraClip; leaves open impact on mortality and need for targeted strategies.
INTRODUCTION: Percutaneous mitral valve repair with Mitraclip device has been approved for the treatment of symptomatic mitral valve regurgitation in patients deemed high surgical risk. It's unclear whether the presence of preexisting coronary arterial disease (CAD) affects the postprocedural outcomes of Mitraclip. METHODS: The study population was extracted from the 2016 Nationwide Readmissions Data (NRD) using the International Classification of Diseases, Tenth Revision, Clinical Modifications/Procedure Coding System (ICD-10-CM/PCS) for Mitraclip, preexisting CAD, and postprocedural complications. Study primary endpoints included in-hospital all-cause mortality, cardiogenic shock, acute myocardial infarction (AMI), acute kidney injury (AKI), stroke, acute respiratory failure, length of hospital stay (LOS), and 30-day readmission rate. RESULTS: A total of 2,539 discharges that had Mitraclip during the index hospitalization, 62.3% had history of preexisting CAD. Mean age was 78.5 years and 46.6% were female. Overall, the presence of preexisting CAD was associated with higher AMI (1.6 vs. 0.4%, p < .01), however, there was no significant differences in terms of in-hospital all-cause mortality (2.2 vs. 2.6%, p = .52), cardiogenic shock (3.4 vs. 4.1%, p = .39), AKI (14.7 vs. 13.6%, p = .43), stroke (0.9 vs. 0.5%, p = .31), acute respiratory failure (9.7 vs. 8.8%, p = .43), LOS (5.3 vs. 5.3 days, p = .85) or 30-day readmission rate (14.6 vs. 14.4%, p = .92). These results persisted after adjustment for baseline characteristics. The subgroup of CAD patients who received percutaneous coronary intervention (PCI) was associated with higher in-hospital mortality (22.5 vs. 2.0%, p < .01), cardiogenic shock (25.0 vs. 3.3%, p < .01), AMI (22.5 vs. 0.8%, p < .01), AKI (55.0 vs. 13.7%, p < .01), stroke (10.0 vs. 0.6%, p < .01), acute respiratory failure (45.0 vs. 8.8%, p < .01), and longer LOS (21.5 vs. 5.1 days, p < .01), however there was no significant difference in 30-day readmission rate (15.0 vs. 14.5%, p = .95). CONCLUSIONS: Preexisting CAD was associated with higher in-hospital AMI post-Mitraclip but with comparable mortality and other morbidities. Patients who received PCI during the same index hospitalization had higher in-hospital mortality and morbidity.
No takes yet. Share an insight, caveat, or question.
Gifft et al. (2020) conducted a cohort in symptomatic mitral valve regurgitation (n=2,539). Preexisting coronary arterial disease (CAD) vs. No preexisting CAD was evaluated on in-hospital all-cause mortality (p=.52). Preexisting coronary artery disease in patients undergoing MitraClip was associated with higher in-hospital acute myocardial infarction (1.6% vs 0.4%, p<0.01) but similar mortality (2.2% vs 2.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: